Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index; 40 of the 54 sources its claims cite were checked for support.
Abstract
Basic and clinical studies demonstrate that depression is associated with reduced size of brain regions that regulate mood and cognition, including the prefrontal cortex and the hippocampus, and decreased neuronal synapses in these areas. Antidepressants can block or reverse these neuronal deficits, although typical antidepressants have limited efficacy and delayed response times of weeks to months. A notable recent discovery shows that ketamine, a N -methyl- d -aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants. Basic studies show that ketamine rapidly induces synaptogenesis and reverses the synaptic deficits caused by chronic stress. These findings highlight the central importance of homeostatic control of mood circuit connections and form the basis of a synaptogenic hypothesis of depression and treatment response.
Overview
CoChat Summary
TL;DR
The paper proposes a synaptogenic hypothesis of depression: stress and depression cause synaptic loss and neuronal atrophy in mood-related circuits, while rapid-acting ketamine reverses these deficits through glutamate burst, BDNF, mTOR, and synaptogenesis. It contrasts slow typical antidepressants with ketamine and highlights new therapeutic targets.
Key findings
- Depression is associated with decreased volume of cortical and limbic regions such as the prefrontal cortex (PFC) and hippocampus, and postmortem studies report decreased synapse number in the dorsolateral PFC, reduced pyramidal neuron size but not number, decreased GABAergic interneurons and glia, and altered GABA/glutamate cycling.
- Chronic stress in rodents reduces apical dendrite length and branching and decreases spine synapse number and function in layer V pyramidal neurons of the medial PFC; atrophy is observed after as little as 1 week of restraint stress (20 to 30 min per day), and chronic stress also decreases adult hippocampal neurogenesis and medial PFC glia.
- Ketamine produces rapid antidepressant responses within hours in treatment-resistant depressed patients, with effects sustained for 7 to 10 days; in rodents it rapidly induces synaptogenesis, reverses spine density deficits and anhedonia/anxiety caused by 3 weeks of chronic stress, and requires mTOR signaling, BDNF, Arc, and GSK3 inhibition.
- Typical antidepressants such as SSRIs take weeks to months to produce therapeutic response and leave more than one-third of depressed individuals resistant; they increase neurotrophic factor expression and plasticity slowly, whereas ketamine more profoundly affects fast excitatory glutamate transmission, BDNF release, and synaptogenesis.
Methods
- Review/perspective article synthesizing basic and clinical literature; no new primary data are reported.
- Evidence reviewed includes human brain-imaging and postmortem MDD studies, rodent chronic stress models (e.g., chronic unpredictable stress, restraint stress), and pharmacological studies of typical antidepressants and ketamine.
- Narrative synthesis comparing mechanisms of typical antidepressants and ketamine and proposing a synaptogenic hypothesis; no systematic review or meta-analysis is described.
Limitations
- Stated in the paper: MDD neurobiology remains poorly understood due to lack of biomarkers, relatively low heritability, and heterogeneity of precipitating factors; imaging provides connectivity information but not the integrity and efficiency of connections; postmortem neuronal morphology studies are hampered by poor fixation and tissue condition; preclinical interpretation is limited by available animal models, and additional human imaging is needed to confirm ketamine circuitry.
- Stated in the paper: ketamine’s psychotomimetic effects and abuse potential limit its development and use; clinical response to NR2B selective agents does not appear as rapid as ketamine, and further studies are needed; many molecular alterations in depression cannot always be distinguished from medication status because studies are not always sufficiently powered.
- Evident from the text: as a review, it does not provide a systematic search strategy, quality assessment, or primary quantitative synthesis; many mechanistic conclusions rely on rodent models and correlational human postmortem/imaging findings.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
27 Valid · 0 Not valid · 4 Not checked · 6 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Studies of neuronal morphology in human postmortem brain tissue have been hampered by poor fixation and tissue condition, but we recently reported that the number of synapses, determined by electron microscopy, is decreased in the dlPFC of depressed patients (16).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Neuronal Atrophy and Synaptic Loss in Depression
What the sources say
- Supportedcites [16] Kang HJ Nat. Med 2012 18 1413 22885997 PMC3491115 source
The paper reports a marked decrease in spine synapse number in the dorsolateral prefrontal cortex of subjects with major depressive disorder compared with controls. Its Electronic Microscopic Stereology methods describe counting those synapses in postmortem tissue using electron micrographs. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A notable recent discovery shows that ketamine, a N-methyl-D-aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants.”
- Also stated in: § Abstract · boosted
“Recent studies report what is arguably the most important discovery in half a century: the therapeutic agent ketamine that produces rapid (within hours) antidepressant actions in treatment-resistant depressed patients (4, 5).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Abstract
What the sources say
- Not checked — no full text of the sourcecites [4] Berman RM Biol. Psychiatry 2000 47 351 10686270 source
- Supportedcites [5] Zarate CA Jr Arch. Gen. Psychiatry 2006 63 856 16894061 source
The Comment section reports a robust antidepressant response to ketamine within hours in treatment-resistant subjects, with improvement over placebo significant from 110 minutes on clinician ratings and 40 minutes on self-ratings. It also identifies ketamine as an NMDA antagonist. Page numbers are not provided in the supplied passages. (LLM, conf=0.94)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · boosted
Every source the paper cites for this claim was checked and supports it.
In the paper
“Chronic unpredictable stress (CUS), a putative model of depression, results in behavioral abnormalities, including core symptoms of depression such as anhedonia (7).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Stress Causes Neuronal Atrophy and Decreases Synaptic Density
What the sources say
- Supportedcites [7] Li N Biol. Psychol 2011 69 754 source
The Conclusions describe CUS as a paradigm that results in anhedonia, a core symptom of depression. The Results report that CUS-exposed rats showed reduced sucrose preference, indicating anhedonia, and increased latency to feed in a novel environment, indicating another behavioral abnormality. (LLM, conf=0.94)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“We have found that infusion of rapamycin into the medial PFC, but not the dorsal striatum, blocks the effects of systemic ketamine administration (6).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Rapid-Acting Antidepressants Increase Synaptogenesis
What the sources say
- Partly supportedcites [6] Li N Science 2010 329 959 20724638 PMC3116441 sourceExperimental — accuracy not yet measured
The passage on behavioral tests (labeled Abstract; Fig. 3D–F) reports that local rapamycin infusion into the medial PFC completely blocked ketamine’s effects in the forced swim and novelty-suppressed feeding tests. Our copy does not report a dorsal-striatum infusion or establish that it failed to block those effects, so the regional comparison is unsupported. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, the synaptogenic actions of ketamine are blocked in mice with a knock-in of the BDNF Met allele that impairs BDNF mRNA transport to dendrites, as well as in conditional BDNF mutant mice (32, 49).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Rapid-Acting Antidepressants Increase Synaptogenesis
What the sources say
- Not matchedcites [32] Liu R Biol. Psychol 2012 71 996
Its entry has no title and year that we can search by.
- Partly supportedcites [49] Autry AE Nature 2011 475 91 21677641 PMC3172695 sourceExperimental — accuracy not yet measured
The Abstract (page not provided) reports that ketamine did not produce antidepressant-like behavioural effects in inducible BDNF knockout mice. It does not report that ketamine’s synaptogenic effects were blocked in those mice, or describe BDNF Met knock-in mice or impaired dendritic mRNA transport. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Not matched
14 more claims · 10 with their cited sources checked
Create a free account to see all 37 claims and every source verdict.
- It may state two separate claims as one. 17
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While synaptic plasticity is a well-known key mechanism in learning and memory (Dayan and Cohen, 2011;Kandel, 2001), unequivocal studies suggest that dysfunction of synaptic plasticity with neuronal atrophy and cell death contribute to the pathophysiology of depression and therapeutic response could be associated with overcoming this deficit (Duman and Aghajanian, 2012;Krystal et al., 2013;Shakesb”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Duman and Aghajanian, 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, synaptic dysfunctions with neuronal atrophy and reductions of glial and GABAergic interneurons in the dorsolateral prefrontal cortex (dlPFC) are found in post-mortem analyses of brains of depressive patients (and animal models of chronic unpredictable stress; Duman and Aghajanian, 2012; Underwood et al., 2012).”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Duman and Aghajanian, 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Broadly, positive valence system deficits are linked primarily to altered dopaminergic and/or opioid signaling within midbrain striatal circuits 94,101 , but may intersect with plasticity impairments and dysconnectivity of excitatory glutamatergic synapses in an overlapping prefrontal-mesolimbic circuit 5 to produce the full spectrum of affective biases seen in depression.”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Such complex effects seem to ultimately result in increased neurogenesis and synaptogenesis, improved neuroplasticity, and normalization of stress-related neurodegeneration [77,78].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Postmortem findings from these animal models consistently demostrate that stress induces synaptic dysfunction [5,6,135], including reductions in synaptic density, as measured by both quantification of synaptic structure and assessments of synaptic protein expression”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [6]
Experimental — accuracy not yet measured
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Self-citationNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Neurocircuitry of Mood Disorders
Price, J. L., & Drevets, W. C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.104 · Cited by 1,606
Research works printed but not linked: 1
- 10.1016/j.pbb.2011.09.010 · DOI · Paper page
Cited by
Items 201–300 of 1,640
Uncoupling DAPK1 from NMDA receptor GluN2B subunit exerts rapid antidepressant-like effects
Li, S.-X., Han, Y., Xu, L.-Z., Yuan, K., Zhang, R.-X., Sun, C.-Y., Xu, D.-F., Yuan, M., Deng, J.-H., Meng, S.-Q., et al. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.85 · Cited by 98
Roy, S. M., Grum-Tokars, V. L., Schavocky, J. P., Saeed, F., Staniszewski, A., Teich, A. F., Arancio, O., Bachstetter, A. D., Webster, S. J., Van Eldik, L. J., et al. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00002 · Cited by 99
Jafarinia, M., Afarideh, M., Tafakhori, A., Arbabi, M., Ghajar, A., Noorbala, A. A., Saravi, M. A., Agah, E., & Akhondzadeh, S. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.05.076 · Cited by 104
Ketamine’s effect on inflammation and kynurenine pathway in depression: A systematic review
Kopra, E., Mondelli, V., Pariante, C., & Nikkheslat, N. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211026426 · Cited by 97
“Ketamine, a noncompetitive antagonist of the glutamate N-methyl-D-aspartate (NMDA) receptor, has been referred to as one of the most important discoveries in antidepressant research in half a century (Duman and Aghajanian, 2012).”
BackgroundLener, M. S., & Iosifescu, D. V. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12759 · Cited by 97
Roles of microglia in adult hippocampal neurogenesis in depression and their therapeutics
Fang, S., Wu, Z., Guo, Y., Zhu, W., Wan, C., Yuan, N., Chen, J., Hao, W., Mo, X., Guo, X., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1193053 · Cited by 96
ECM receptors in neuronal structure, synaptic plasticity, and behavior
Kerrisk, M. E., Cingolani, L. A., & Koleske, A. J. (2014) · Progress in Brain Research · doi:10.1016/b978-0-444-63486-3.00005-0 · Cited by 96
“These defects are hallmarks of schizophrenia (Glantz and Lewis, 2000; Kalus et al., 2000; Law et al., 2004), depression (Cotter et al., 2001; Duman and Aghajanian, 2012), intellectual disability (Kaufmann and Moser, 2000; Kaufmann et al., 2000; Ramakers, 2000), autism spectrum disorders (ASDs) (Won…”
Targeting opioid dysregulation in depression for the development of novel therapeutics
Browne, C. A., & Lucki, I. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.009 · Cited by 95
“Moreover, aberrant neuronal firing and synaptic plasticity deficits are characteristic features of rodent models of stress and depression (Duman & Aghajanian, 2012; Howe & Kenny, 2018; Lutz & Kieffer, 2013; Ota & Duman, 2013).”
BackgroundDim light at night increases depressive-like responses in male C3H/HeNHsd mice
Fonken, L. K., & Nelson, R. J. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.12.046 · Cited by 95
“Moreover, BDNF affects dendrite omplexity, spine density, and function [5].”
Dunlap, L. E., Azinfar, A., Ly, C., Cameron, L. P., Viswanathan, J., Tombari, R. J., Myers-Turnbull, D., Taylor, J. C., Grodzki, A. C., Lein, P. J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01404 · Cited by 95
“5-MeO-DMT (28) and 6-MeO-isoDMT (6); or 6MeO-DMT (30) and 5-MeO-isoDMT (5)) was more likely (Figure 10C; 50.”
BackgroundMethodInfluentialGreenway, K. T., Garel, N., Jerome, L., & Feduccia, A. A. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1772054 · Cited by 94
“described by at least one expert as ‘arguably the most important discovery in half a century’ [16].”
BackgroundWu, M., Minkowicz, S., Dumrongprechachan, V., Hamilton, P., & Kozorovitskiy, Y. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.12.022 · Cited by 95
Zhang, C., Li, Z., Wu, Z., Chen, J., Wang, Z., Peng, D., Hong, W., Yuan, C., Wang, Z., Yu, S., et al. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3297-0 · Cited by 99
“In clinical practice, reports have indicated that among patients with MDD, ketamine alleviates depressive symptoms within hours, especially delivered to those with TRD in an anesthetic medication, whereas the therapeutic effects of selective serotonin reuptake inhibitor (SSRI) are sustained for 7–10 days (Duman and Ag…”
BackgroundDuncan, W. C., Slonena, E., Hejazi, N. S., Brutsche, N., Yu, K. C., Park, L., Ballard, E. D., & Zarate, C. A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.03.011 · Cited by 93
Psilocybin’s lasting action requires pyramidal cell types and 5-HT2A receptors
Shao, L.-X., Liao, C., Davoudian, P. A., Savalia, N. K., Jiang, Q., Wojtasiewicz, C., Tan, D., Nothnagel, J. D., Liu, R., Woodburn, S. C., et al. (2025) · Nature · doi:10.1038/s41586-025-08813-6 · Cited by 138
“It has been hypothesized that antidepressants may work by forming and strengthening synapses in the prefrontal cortex, which counteracts synaptic dysfunction in depression 11 .”
Antidepressant-like effects of Xiaochaihutang in a rat model of chronic unpredictable mild stress
Su, G. Y., Yang, J., Wang, F., Ma, J., Zhang, K., Dong, Y. X., Song, S. J., Lu, X. M., & Wu, C. F. (2014) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2014.01.006 · Cited by 93
“The synthetic antidepressants produce therapeutic responses, while one-third patients remained treatment-resistant (Rush et al., 2006; Duman and Aghajanian, 2012; Hsu et al., 2012) and even suffered adverse-effects such as cardiotoxicity, hypertensive crisis, sexual dysfunction, and sleep disorder (Khurana and Baudend…”
BackgroundA critical role for VEGF and VEGFR2 in NMDA receptor synaptic function and fear-related behavior
De Rossi, P., Harde, E., Dupuis, J. P., Martin, L., Chounlamountri, N., Bardin, M., Watrin, C., Benetollo, C., Pernet-Gallay, K., Luhmann, H. J., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.195 · Cited by 94
Novel glutamatergic drugs for the treatment of mood disorders
Murrough, J., Lapidus, K., & Soleimani, L. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s36689 · Cited by 92
“Recently, ketamine was found to rapidly increase synaptic density and signaling in cortical neurons in conjunction with rapid antidepressant effects in animal models and to reverse stress-induced trophic deficits following chronic mild stress.(34) Differences in dose and duration of exposure are likely critical variab…”
Drug addiction: a curable mental disorder?
Liu, J., & Li, J. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0180-x · Cited by 119
The Role of Chronic Stress in Anxious Depression
Ross, R. A., Foster, S. L., & Ionescu, D. F. (2017) · Chronic Stress · doi:10.1177/2470547016689472 · Cited by 92
“, the ventral tegmental area)—have been implicated in the resultant emotional dysregulation and anhedonia observed in depression.(36,37) Furthermore, activity in the default mode network (networks in the brain that are active at ‘‘rest’’ but relatively inactive during active task performance) appears to be increased i…”
BackgroundKetamine-Associated Brain Changes: A Review of the Neuroimaging Literature
Ionescu, D. F., Felicione, J. M., Gosai, A., Cusin, C., Shin, P., Shapero, B. G., & Deckersbach, T. (2018) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000179 · Cited by 91
Yang, B., Zhang, J.-C., Han, M., Yao, W., Yang, C., Ren, Q., Ma, M., Chen, Q.-X., & Hashimoto, K. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4399-2 · Cited by 91
“In addition, we performedWestern blot analysis of brain-derived neurotrophic factor (BDNF)TrkB pathway, postsynaptic density protein 95 (PSD-95), and the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor (GluA1), both of which are required for synaptic plasticity in selected brain regions, since BDN…”
BackgroundMethodThe promise of ketamine for treatment‐resistant depression: current evidence and future directions
DeWilde, K. E., Levitch, C. F., Murrough, J. W., Mathew, S. J., & Iosifescu, D. V. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12646 · Cited by 89
Trapp, N. T., Purgianto, A., Taylor, J. J., Singh, M. K., Oberman, L. M., Mickey, B. J., Youssef, N. A., Solzbacher, D., Zebley, B., Cabrera, L. Y., et al. (2025) · Clinical Neurophysiology · doi:10.1016/j.clinph.2024.12.015 · Cited by 89
Musazzi, L., Treccani, G., & Popoli, M. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00060 · Cited by 83
Kvarta, M. D., Bradbrook, K. E., Dantrassy, H. M., Bailey, A. M., & Thompson, S. M. (2015) · Journal of Neurophysiology · doi:10.1152/jn.00359.2015 · Cited by 86
“That is, pathological chronic elevation of GCs causes depressive-like behavioral changes because it weakens specific subsets of synapses in corticomesolimbic circuits, such as the hippocampus, PFC (Duman and Aghajanian 2012; Yuen et al. 2012), and ventral striatum (Lim et al. 2012), thereby resulting in the anhedonia…”
BackgroundInfluentialThe Ups and Downs of Modelling Mood Disorders in Rodents
Slattery, D. A., & Cryan, J. F. (2014) · ILAR Journal · doi:10.1093/ilar/ilu026 · Cited by 85
Ketamine treatment for refractory anxiety: A systematic review
Tully, J. L., Dahlén, A. D., Haggarty, C. J., Schiöth, H. B., & Brooks, S. J. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15374 · Cited by 104
“Refractory anxiety may cause glutamate receptor damage in the hippocampus and neuronal atrophy in the prefrontal cortex (PFC), which can result in mood disturbances and cognitive deficits.(17) NMDA receptor inhibitors have been shown to restore hippocampal function in the stressed brain by reducing NMDA receptor activ…”
BackgroundSun, Y., Blumberger, D. M., Mulsant, B. H., Rajji, T. K., Fitzgerald, P. B., Barr, M. S., Downar, J., Wong, W., Farzan, F., & Daskalakis, Z. J. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0302-8 · Cited by 85
Sun, H.-L., Zhou, Z.-Q., Zhang, G.-F., Yang, C., Wang, X.-M., Shen, J.-C., Hashimoto, K., & Yang, J.-J. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.21 · Cited by 84
Isoflurane produces antidepressant effects and induces TrkB signaling in rodents
Antila, H., Ryazantseva, M., Popova, D., Sipilä, P., Guirado, R., Kohtala, S., Yalcin, I., Lindholm, J., Vesa, L., Sato, V., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-08166-9 · Cited by 84
Role of glutamate receptors and glial cells in the pathophysiology of treatment-resistant depression
Kim, Y.-K., & Na, K.-S. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.03.009 · Cited by 84
Kokkosis, A. G., Madeira, M. M., Hage, Z., Valais, K., Koliatsis, D., Resutov, E., & Tsirka, S. E. (2024) · Glia · doi:10.1002/glia.24464 · Cited by 84
“It is known that synaptic dysfunction is associated with the regulation of mood in mPFC (Duman & Aghajanian, 2012) and microglia modulate synaptic reorganization and circuitry refinement through synaptic pruning in the adult brain (Schafer et al., 2012).”
BackgroundMitochondrial fission drives neuronal metabolic burden to promote stress susceptibility in male mice
Dong, W., Long, L., Deng, Q., Liu, D., Wang, J., Wang, F., & Chen, J. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00924-6 · Cited by 97
Rossetti, A. C., Papp, M., Gruca, P., Paladini, M. S., Racagni, G., Riva, M. A., & Molteni, R. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.10.022 · Cited by 96
Wang, W., Guo, H., Zhang, S.-X., Li, J., Cheng, K., Bai, S.-J., Yang, D.-Y., Wang, H.-Y., Liang, Z.-H., Liao, L., et al. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00577 · Cited by 84
State-Dependent Partial Occlusion of Cortical LTP-Like Plasticity in Major Depression
Kühn, M., Mainberger, F., Feige, B., Maier, J. G., Mall, V., Jung, N. H., Reis, J., Klöppel, S., Normann, C., & Nissen, C. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.310 · Cited by 93
Welcome, M. O. (2020) · Inflammopharmacology · doi:10.1007/s10787-020-00712-8 · Cited by 96
Du, M., Wu, C., Yu, R., Cheng, Y., Tang, Z., Wu, B., Fu, J., Tan, W., Zhou, Q., Zhu, Z., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01711-7 · Cited by 89
“In addition, synaptic damage can further contribute to affective disorders [63, 64].”
BackgroundYang, Z., Zhou, D., Li, H., Cai, X. M., Liu, W., Wang, L., Chang, H., Li, M., & Xiao, X. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0592-0 · Cited by 85
Ketamine as a Fast Acting Antidepressant: Current Knowledge and Open Questions
Salvadore, G., & Singh, J. B. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12103 · Cited by 81
“, 2012 for a comprehensive review on the topic [22]).”
BackgroundModulation of synaptic plasticity by exercise
Bettio, L. E. B., Thacker, J. S., Hutton, C. P., & Christie, B. R. (2019) · International review of neurobiology · doi:10.1016/bs.irn.2019.07.002 · Cited by 96
Lazarevic, V., Yang, Y., Flais, I., & Svenningsson, P. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01246-3 · Cited by 81
Liver Soluble Epoxide Hydrolase Regulates Behavioral and Cellular Effects of Chronic Stress
Qin, X.-H., Wu, Z., Dong, J.-H., Zeng, Y.-N., Xiong, W.-C., Liu, C., Wang, M.-Y., Zhu, M.-Z., Chen, W.-J., Zhang, Y., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.11.006 · Cited by 80
Ketamine administration reduces amygdalo‐hippocampal reactivity to emotional stimulation
Scheidegger, M., Henning, A., Walter, M., Lehmann, M., Kraehenmann, R., Boeker, H., Seifritz, E., & Grimm, S. (2016) · Human Brain Mapping · doi:10.1002/hbm.23148 · Cited by 79
“An increased prefrontal–hippocampal connectivity 20 min post ketamine infusion as reported by this study supports the notion of a dynamic reorganization of functional networks as a result of downstream effects of ketamine on synaptic plasticity [Duman and Aghajanian, 2012].”
Jiménez-Sánchez, L., Campa, L., Auberson, Y. P., & Adell, A. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.123 · Cited by 85
“…increase in glutamate induced by NVP-AAM077 and its action on AMPA receptors can contribute to the release of BDNF and subsequent increase in synaptogenesis (Duman and Aghajanian, 2012), and synaptic plasticity (Maeng et al., 2008), which may be suggestive of an effective antidepressant action.”
The protective effects of Ghrelin/GHSR on hippocampal neurogenesis in CUMS mice
Huang, H., Chen, X., Han, Q.-Q., Wang, J., Pilot, A., Yu, R., Liu, Q., Li, B., Wu, G.-C., Wang, Y., et al. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.05.013 · Cited by 83
Tang, X.-H., Zhang, G.-F., Xu, N., Duan, G.-F., Jia, M., Liu, R., Zhou, Z.-Q., & Yang, J.-J. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01843-z · Cited by 79
Is depression the missing link between inflammatory mediators and cancer?
Polityńska, B., Pokorska, O., Wojtukiewicz, A. M., Sawicka, M., Mysliwiec, M., Honn, K. V., Tucker, S. C., & Wojtukiewicz, M. Z. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108293 · Cited by 89
Cathomas, F., Azzinnari, D., Bergamini, G., Sigrist, H., Buerge, M., Hoop, V., Wicki, B., Goetze, L., Soares, S., Kukelova, D., et al. (2019) · Genes, Brain and Behavior · doi:10.1111/gbb.12475 · Cited by 78
“In depression, relative to control subjects, changes in neurons (Duman & Aghajanian, 2012; Rajkowska et al. , 1999; Rajkowska et al. , 2007) and glia (Rajkowska & Miguel-Hidalgo, 2007; Rajkowska & Stockmeier, 2013) have been identified in human post-mortem brain tissue.”
The nucleus reuniens: a key node in the neurocircuitry of stress and depression
Kafetzopoulos, V., Kokras, N., Sotiropoulos, I., Oliveira, J. F., Leite‐Almeida, H., Vassalou, A., Sardinha, V. M., Papadopoulou‐Daifoti, Z., Almeida, O. F. X., Antoniou, K., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.55 · Cited by 85
Liu, H., Zhang, X., Shi, P., Yuan, J., Jia, Q., Pi, C., Chen, T., Xiong, L., Chen, J., Tang, J., et al. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02768-z · Cited by 92
“Therefore, the Glu system might play a crucial role in the pathogenesis of emotional disorders, such as the dysfunction of Glu neurotransmissions in the cerebral cortex and marginal regions, which are closely related to depression [83, 84].”
BackgroundHippocampal volume and the rapid antidepressant effect of ketamine
Abdallah, C. G., Salas, R., Jackowski, A., Baldwin, P., Sato, J. R., & Mathew, S. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114544776 · Cited by 78
“A major focus of MDD research is to understand the mechanisms underlying the rapid-acting antidepressant effects of ketamine (Duman and Aghajanian, 2012).”
BackgroundHippocampal Neurogenesis and Antidepressive Therapy: Shocking Relations
Rotheneichner, P., Lange, S., O’Sullivan, A., Marschallinger, J., Zaunmair, P., Geretsegger, C., Aigner, L., & Couillard-Despres, S. (2014) · Neural Plasticity · doi:10.1155/2014/723915 · Cited by 78
“demonstrated for pharmacological treatments, ECT might stop dendritic atrophy [38, 39] or increase dendritic spine density in various cortical and limbic structures [40, 41].”
BackgroundBerk, M., Williams, L. J., Andreazza, A. C., Pasco, J. A., Dodd, S., Jacka, F. N., Moylan, S., Reiner, E. J., & Magalhaes, P. V. S. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005142 · Cited by 77
“It is worth mentioning that ketamine, a N-methyl-D-aspartate receptor antagonist that, in turn, increases presynaptic glutamate release, has emerged as a new drug for depression treatment.(44) Similarly, lead impacts many pathways known to be operative in the genesis of depression, including neurogenesis and apoptosis…”
The Swedish Bipolar Study Group, Chang, H., MooDS Bipolar Consortium, Hoshina, N., Zhang, C., Ma, Y., Cao, H., Wang, Y., Wu, D.-D., Bergen, S. E., et al. (2018) · Molecular Psychiatry · doi:10.1038/mp.2016.231 · Cited by 76
Music prevents stress-induced depression and anxiety-like behavior in mice
Fu, Q., Qiu, R., Chen, L., Chen, Y., Qi, W., & Cheng, Y. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02606-z · Cited by 101
Kang, M. J. Y., Hawken, E., & Vazquez, G. H. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.860882 · Cited by 77
Circadian Mechanisms Underlying Reward-Related Neurophysiology and Synaptic Plasticity
Parekh, P. K., & McClung, C. A. (2016) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00187 · Cited by 82
Ketamine, Sleep, and Depression: Current Status and New Questions
Duncan, W. C., & Zarate, C. A. (2013) · Current Psychiatry Reports · doi:10.1007/s11920-013-0394-z · Cited by 76
Xu, P., Wang, K. Z., Lü, C., Dong, L., Zhai, J. L., Liao, Y. H., Aibai, S., Yang, Y., & Liu, X. M. (2016) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.09.023 · Cited by 80
“However, the available antidepressants caused treatment-resistant in one-third patients(Rush et al., 2006; Duman and Aghajanian, 2012) and many of them lead to undesirable adverse-effects such as cardiotoxicity, hypertensive crisis and sleep disorder (Khurana and Baudendistel, 2003).”
BackgroundYang, Y., Ju, W., Zhang, H., & Sun, L. (2018) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2018.00229 · Cited by 75
Kong, H., Zeng, X., Fan, Y., Yuan, S., Ge, S., Xie, W., Wang, H., & Hu, G. (2014) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12222 · Cited by 72
“Despite the extensive research, the neurobiology of depression remains poorly understood due to low rates of heritability and heterogeneity of precipitating factors [2].”
BackgroundChen, X., Luo, J., Leng, Y., Yang, Y., Zweifel, L. S., Palmiter, R. D., & Storm, D. R. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.12.012 · Cited by 74
“MDD is familial but has low heritability compared to other major psychiatric disorders [1, 4, 5, 13].”
BackgroundGilbert, J. R., & Zarate, C. A. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172856 · Cited by 73
“This synaptic potentiation and synaptogenesis has been posited to ultimately form the foundation of ketamine’s antidepressant effectiveness (Autry et al., 2011; Duman and Aghajanian, 2012; Nosyreva et al., 2013).”
BackgroundMicroRNA-dependent control of neuroplasticity in affective disorders
Martins, H. C., & Schratt, G. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01379-7 · Cited by 74
Sakayori, N., Kikkawa, T., Tokuda, H., Kiryu, E., Yoshizaki, K., Kawashima, H., Yamada, T., Arai, H., Kang, J. X., Katagiri, H., et al. (2015) · Stem Cells · doi:10.1002/stem.2246 · Cited by 80
Sun, N., Lei, L., Wang, Y., Yang, C., Liu, Z., Li, X., & Zhang, K. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.01.017 · Cited by 74
Caraci, F., Calabrese, F., Molteni, R., Bartova, L., Dold, M., Leggio, G. M., Fabbri, C., Mendlewicz, J., Racagni, G., Kasper, S., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014977 · Cited by 73
“…alterations, including neuronal atrophy, reduced number of spines, and dendritic arborization have been consistently re-ported in the prefrontal cortex and hippocampus of depressed patients (Rajkowska et al., 1999; McEwen and Lasley, 2003; Stockmeier et al., 2004; Duman and Aghajanian, 2012).”
BackgroundWang, M., Li, P., Li, Z., da Silva, B. S., Zheng, W., Xiang, Z., He, Y., Xu, T., Cordeiro, C., Deng, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37601-x · Cited by 73
Ge, J., Qi, C., & Zhou, J. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.04.020 · Cited by 85
Treccani, G., Ardalan, M., Chen, F., Musazzi, L., Popoli, M., Wegener, G., Nyengaard, J. R., & Müller, H. K. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1613-3 · Cited by 73
Veldman, M. B., Park, C. S., Eyermann, C. M., Zhang, J. Y., Zuniga-Sanchez, E., Hirano, A. A., Daigle, T. L., Foster, N. N., Zhu, M., Langfelder, P., et al. (2020) · Neuron · doi:10.1016/j.neuron.2020.07.019 · Cited by 71
“Thus, the availability of simple and scalable genetic tools to study the morphology of neurons and glial cells will help answer some important questions related to mammalian brain cell biology (Zeng and Sanes, 2017; Swanson and Lichtman, 2016) and pathology (Duman and Aghajanian, 2012; Adalbert and Coleman, 2013).”
BackgroundAcetate supplementation produces antidepressant-like effect via enhanced histone acetylation
Huang, W., Hu, W., Cai, L., Zeng, G., Fang, W., Dai, X., Ye, Q., Chen, X., & Zhang, J. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.11.121 · Cited by 80
Differential induction of FosB isoforms throughout the brain by fluoxetine and chronic stress
Vialou, V., Thibault, M., Kaska, S., Cooper, S., Gajewski, P., Eagle, A., Mazei-Robison, M., Nestler, E. J., & Robison, A. J. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.07.005 · Cited by 72
“…et al., 2010, 2014), and we chose hippocampus because is both modulates the function of the mesolimbic and mesocortical dopamine system and has been directly implicated in many studies of depression, both in humans and in pre-clinical models (Duman and Aghajanian, 2012; Eisch and Petrik, 2012).”
Gruner (2017) · doi:10.1016/j.neuroscience.2016.11.029 · Cited by 72
Numa, C., Nagai, H., Taniguchi, M., Nagai, M., Shinohara, R., & Furuyashiki, T. (2019) · Scientific Reports · doi:10.1038/s41598-019-52997-7 · Cited by 71
Shen, C., Cao, K., Cui, S., Cui, Y., Mo, H., Wen, W., Dong, Z., Lin, H., Bai, S., Yang, L., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109787 · Cited by 71
Réus, G. Z., Nacif, M. P., Abelaira, H. M., Tomaz, D. B., dos Santos, M. A. B., Carlessi, A. S., da Luz, J. R., Gonçalves, R. C., Vuolo, F. S., Dal‐Pizzol, F., et al. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.10.022 · Cited by 75
Leuchter, A. F., Hunter, A. M., Krantz, D. E., & Cook, I. A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12742 · Cited by 71
Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review
D. Rosenblat, J., S. McIntyre, R., S. Alves, G., N. Fountoulakis, K., & F. Carvalho, A. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150630175044 · Cited by 71
“A relative decrease in neurotrophins centrally and peripherally has been implicated in the pathoetiology of MDD [126].”
BackgroundInfluentialZhu, Z., Wang, G., Ma, K., Cui, S., & Wang, J. (2017) · Oncotarget · doi:10.18632/oncotarget.16411 · Cited by 75
Adult hippocampal neurogenesis: Is it the alpha and omega of antidepressant action?
Eliwa, H., Belzung, C., & Surget, A. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.08.005 · Cited by 78
Jiang, P., Dang, R.-L., Li, H.-D., Zhang, L.-H., Zhu, W.-Y., Xue, Y., & Tang, M.-M. (2014) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2014/729827 · Cited by 70
“A number of animal studies have documented that the exposure to chronic stress can result in decreased BDNF expression in hippocampus [5].”
BackgroundBeyond the neuron: Role of non-neuronal cells in stress disorders
Cathomas, F., Holt, L. M., Parise, E. M., Liu, J., Murrough, J. W., Casaccia, P., Nestler, E. J., & Russo, S. J. (2022) · Neuron · doi:10.1016/j.neuron.2022.01.033 · Cited by 76
Luoni, A., Macchi, F., Papp, M., Molteni, R., & Riva, M. A. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu061 · Cited by 70
“Specifically, we investigated the neurotrophin BDNF, which plays a role in depression and is also critically involved in drug responsiveness (Kozisek et al., 2008; Calabrese et al., 2010 2011; Krishnan and Nestler, 2010; Autry and Monteggia, 2012).”
BackgroundResultInfluentialMa, M., Ren, Q., Yang, C., Zhang, J.-C., Yao, W., Dong, C., Ohgi, Y., Futamura, T., & Hashimoto, K. (2017) · Psychopharmacology · doi:10.1007/s00213-016-4483-7 · Cited by 69
Exposure to Stressors Facilitates Long-Term Synaptic Potentiation in the Lateral Habenula
Park, H., Rhee, J., Park, K., Han, J.-S., Malinow, R., & Chung, C. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2281-16.2017 · Cited by 70
“Acute stress exposure has also been reported to facilitate LTP induction in the hippocampus-PFC pathway (Goto and Grace, 2006), whereas chronic stress exposure was shown to impair LTP induction in the PFC (Cerqueira et al., 2007).”
BackgroundAbdallah, C. G., Dutta, A., Averill, C. L., McKie, S., Akiki, T. J., Averill, L. A., & William Deakin, J. F. (2018) · Chronic Stress · doi:10.1177/2470547018796102 · Cited by 70
“Moreover, the reversal of synaptic dysconnectivity appears to be a necessary step to exert antidepressant effects.(18) Ketamine has been found to robustly reverse the prefrontal synaptic dysconnectivity in animal models of depression and to normalize related network disturbances in humans.”
Duan, W., Cao, D., Wang, S., & Cheng, J. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00375 · Cited by 85
Astrocytic ALKBH5 in stress response contributes to depressive-like behaviors in mice
Guo, F., Fan, J., Liu, J., Kong, P., Ren, J., Mo, J., Lu, C., Zhong, Q., Chen, L.-Y., Jiang, H.-T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48730-2 · Cited by 93
Structural neural plasticity evoked by rapid-acting antidepressant interventions
Liao, C., Dua, A. N., Wojtasiewicz, C., Liston, C. M., & Kwan, A. C. (2024) · Nature reviews. Neuroscience · doi:10.1038/s41583-024-00876-0 · Cited by 87
“Rapid-acting antidepressant drugs have been postulated to target synapses by enhancing neural plasticity 17 , a mechanism that might also be key for other antidepressant interventions, such as electroconvulsive therapy (ECT) 18 and repetitive transcranial magnetic stimulation (TMS) 19 .”
Noda, Y., Zomorrodi, R., Vila-Rodriguez, F., Downar, J., Farzan, F., Cash, R. F. H., Rajji, T. K., Daskalakis, Z. J., & Blumberger, D. M. (2018) · Depression and Anxiety · doi:10.1002/da.22738 · Cited by 68
Adenosine A2A receptor as potential therapeutic target in neuropsychiatric disorders
Domenici, M. R., Ferrante, A., Martire, A., Chiodi, V., Pepponi, R., Tebano, M. T., & Popoli, P. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104338 · Cited by 78
Kaut, O., Schmitt, I., Hofmann, A., Hoffmann, P., Schlaepfer, T. E., Wüllner, U., & Hurlemann, R. (2015) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-014-0572-y · Cited by 68
Novel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression
Wang, Y., Wang, X., Feng, S., Chen, N., Wang, Z., & Zhang, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105761 · Cited by 69
Nrf2 regulates iron-dependent hippocampal synapses and functional connectivity damage in depression
Zeng, T., Li, J., Xie, L., Dong, Z., Chen, Q., Huang, S., Xie, S., Lai, Y., Li, J., Yan, W., et al. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02875-x · Cited by 77
“Basic neuroscience research has demonstrated that chronic stress and depressive-like behaviours are linked to a decrease in the size of brain regions responsible for regulating mood and cognition, particularly the reduction of neuronal synapses in the hippocampus [3, 4].”
BackgroundSachs, B. D., Rodriguiz, R. M., Siesser, W. B., Kenan, A., Royer, E. L., Jacobsen, J. P. R., Wetsel, W. C., & Caron, M. G. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000321 · Cited by 67
“, 2010) and ketamine, which is an NMDA receptor antagonist that has recently demonstrated promise in the treatment of depression (Zarate et al., 2006; Duman and Aghajanian, 2012) and anxiety (Irwin and Iglewicz, 2010).”
BackgroundCaudal, D., Alvarsson, A., Björklund, A., & Svenningsson, P. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.09.002 · Cited by 75
“In this context, it is highly relevant that the current understanding of the neurobiology of depression emphasizes dysregulation of synaptic plasticity (Duman and Aghajanian, 2012).”
Surgery-induced behavioral changes in aged rats
Hovens, I. B., Schoemaker, R. G., van der Zee, E. A., Heineman, E., Nyakas, C. J., & van Leeuwen, B. L. (2013) · Experimental Gerontology · doi:10.1016/j.exger.2013.07.011 · Cited by 69
“Although, the hippocampus is classically associated with learning and memory, it has also been related to aspects of mood (Duman and Aghajanian, 2012; Kubera et al., 2011).”
Background
Metadata
- Authors
- Duman, R. S., & Aghajanian, G. K.
- Affiliations
- Yale University (US)
- Corresponding author
- Duman, Ronald S.
- ORCID
- Duman, Ronald S.
- Venue
- Science
- Published
- 2012-10-05
- Volume
- 338
- Issue
- 6103
- Pages
- 68-72
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4424898
- OpenAlex
- W2157504436
- Cited by
- 1,651
- References
- 57
- Citations by year
- 2026: 176 · 2025: 175 · 2024: 132 · 2023: 138 · 2022: 127 · 2021: 161 · 2020: 125 · 2019: 86 · 2018: 88 · 2017: 93 · 2016: 89 · 2015: 106 · 2014: 78 · 2013: 71 · 2012: 4
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (R01MH093897)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- depression, synaptic dysfunction, synaptogenesis, ketamine, NMDA receptor antagonists, antidepressant resistance, chronic stress, prefrontal cortex, hippocampus, mood regulation, rapid antidepressant response, therapeutic target
- MeSH terms
- Animals, Antidepressive Agents, Atrophy, Behavior, Major Depressive Disorder, Homeostasis, Humans, Neurons, Stress, Psychological, Synapses, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.